50159
document
Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris : a randomized , double-blind , noninferiority study . Efficacy and safety of azithromycin and doxycycline for the treatment of moderate acne vulgaris were evaluated ( 240 patients ) in both intention-to-treat and per-protocol populations . The evaluation of clinical efficacy was based on the change in the number of facial inflammatory lesions from baseline to the end of treatment , and noninferiority was defined by the upper 95 % confidence limit of the difference between two treatments being less than 9 . Reduction in the number of lesions was similar with both azithromycin and doxycycline treatments ( 27 +/- 12 and 30 +/- 12 , respectively ) in both groups . Also , the upper 95 % confidence limit of 5 inflammatory lesions has satisfied the noninferiority criterion . The incidence of adverse events did not differ between the two treatment groups . The shorter and simpler treatment schedule of azithromycin had similar efficacy and safety as doxycycline in the treatment of moderate acne vulgaris , confirming noninferiority of azithromycin as compared with doxycycline .
50160
Intervention_Pharmacological
Pulsed azithromycin treatment
50161
Intervention_Pharmacological
2-week-longer daily doxycycline treatment
50162
Intervention_Pharmacological
azithromycin and doxycycline
50163
Intervention_Pharmacological
azithromycin
50164
Intervention_Pharmacological
doxycycline
50165
Intervention_Pharmacological
azithromycin
50166
Intervention_Pharmacological
doxycycline
50167
Intervention_Pharmacological
azithromycin
50168
Intervention_Pharmacological
doxycycline
50169
Outcome_Physical
number of facial inflammatory lesions
50170
Outcome_Physical
number of lesions
50171
Outcome_Other
efficacy and safety
50172
Participant_Condition
acne vulgaris
50173
Participant_Condition
moderate acne vulgaris
50174
Participant_Sample-size
240
50175
Participant_Condition
moderate acne vulgaris